ProCE Banner Activity

FORTE Subanalysis: Efficacy of KRd With or Without ASCT Followed by KR or R Maintenance in Patients With ND MM According to Cytogenetic Risk Status

Slideset Download
Conference Coverage
Results of this subgroup analysis show that KRd-ASCT, as compared with KRd12, and KR maintenance, as compared with R maintenance, prolonged PFS across all cytogenetic risk groups except patients with amp(1q).

Released: June 11, 2021

Expiration: June 10, 2022

No longer available for credit.

Share

Provided by

Provided by Clinical Care Options, LLC
ProCE Banner

Supporters

Supported by educational grants from

AbbVie

Amgen, Inc.

AstraZeneca

Bristol Myers Squibb

Daiichi Sankyo, Inc.

Exelixis

Gilead Sciences, Inc.

GlaxoSmithKline

Ipsen Biopharmaceuticals Inc

Merck Sharp & Dohme Corp.

Novartis Pharmaceuticals Corporation

Pfizer, Inc.

Pharmacyclics LLC an AbbVie Company and Janssen Biotech Inc

Sanofi Genzyme